Episode 77: Revolution Medicines

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Revolution Medicines, the precision oncology company that spent over a decade trying to drug one of cancer’s most notorious targets: RAS. With mutations present in roughly 30% of all new cancer diagnoses, including pancreatic, lung, and colorectal cancers, RAS has long been considered undruggable. Revolution bet their entire company on proving that wrong. We break down the science behind their tricomplex inhibitor platform, the three lead drugs in their pipeline, daraxonrasib, elironrasib, and zoldonrasib, and the landmark Phase 3 RASolute 302 results that showed unprecedented overall survival in metastatic pancreatic cancer, earned a Plenary presentation at ASCO 2026, and triggered an FDA NDA review. But this is also a story about the pressure of building an ambitious company with no revenue, nearly $1 billion in annual R&D spend, and a failed $30 billion acquisition attempt with Merck that sent the stock crashing 26% in a single day. Revolution walked away from the deal. The question now is whether that confidence was prescient or premature. 🎧 **Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!** https://linktr.ee/maneadkhin #PetriDishPerspectives #RevolutionMedicines #RAS #KRAS #Oncology #PancreaticCancer #LungCancer #Daraxonrasib #Biotech #DrugDiscovery #PrecisionOncology #CancerResearch #FDA #LifeSciences #Healthcare #BiotechTok #BiotechNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.